Immunogenic apoptosis in human acute myeloid leukemia (AML): Primary human AML cells expose calreticulin and release heat shock protein (HSP) 70 and HSP90 during apoptosis

Oncology Reports

Volumn 25, Issue 6, 2011, Pages 1549-1556

  Fredly, Hanne ^a   Ersvær, Elisabeth ^a   Gjertsen, Bjørn Tore ^a   Bruserud, Øystein ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Acute myeloid leukemia; Apoptosis; Calreticulin; Heat shock protein 70; Heat shock protein 90

Indexed keywords

CALRETICULIN; CYTARABINE; DAUNORUBICIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; MITOMYCIN; RETINOIC ACID; THEOPHYLLINE; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER IMMUNOLOGY; CELL STRESS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MALE; PHENOTYPE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN SECRETION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALRETICULIN; CELL LINE, TUMOR; CELL SEPARATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HSP70 HEAT-SHOCK PROTEINS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 79954564425     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1229     Document Type: Article

References (35)

1. Estey E and Dohner H: Acute myeloid leukaemia. Lancet 368: 1894-1907, 2006.
2. Oyan AM, Anensen N, Bo TH, et al: Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer 9: 77, 2009.
3. Solary E, Droin N, Bettaieb A, Corcos L, Dimanche-Boitrel MT and Garrido C: Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies. Leukemia 14: 1833-1849, 2000.
4. Auletta JJ and Lazarus HM: Immune restoration following hematopoietic stem cell transplantation: an evolving target. Bone Marrow Transplant 35: 835-857, 2005.
5. Behl D, Porrata LF, Markovic SN, et al: Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 20: 29-34, 2006.
6. Kim DH, Sohn SK, Won DI, Lee NY, Suh JS and Lee KB: Rapid helper T-cell recovery above 200x10 6/1 at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation. Bone Marrow Transplant 37: 1119-1128, 2006.
7. Parkman R, Cohen G, Carter SL, et al: Successful immune reconstitution decreases leukemic relapse and improves survival in recipients of unrelated cord blood transplantation. Biol Blood Marrow Transplant 12: 919-927, 2006.
8. Porrata LF, Litzow MR, Tefferi A, et al: Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 16: 1311-1318, 2002.
9. Bruserud O, Ersvaer E, Olsnes A and Gjertsen BT: Anticancer immunotherapy in combination with proapoptotic therapy. Curr Cancer Drug Targets 8: 666-675, 2008.
10. Obeid M, Tesniere A, Ghiringhelli F, et al: Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 13: 54-61, 2007.
11. Obeid M, Tesniere A, Panaretakis T, et al: Ecto-calreticulin in immunogenic chemotherapy. Immunol Rev 220: 22-34, 2007.
12. Tesniere A, Panaretakis T, Kepp O, et al: Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 15: 3-12, 2008.
13. Michalak M, Groenendyk J, Szabo E, Gold LI and Opas M: Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum. Biochem J 417: 651-666, 2009.
14. Bernasconi P: Molecular pathways in myelo dysplastic syndromes and acute myeloid leukemia: relationships and distinctions - a review. Br J Haematol 142: 695-708, 2008.
15. Schimmer AD: Novel therapies targeting the apoptosis pathway for the treatment of acute myeloid leukemia Curr Treat Options Oncol 8: 277-286, 2007.
16. Hjelle SM, Forthun RB, Haaland I, et al: Clinical proteomics of myeloid leukemia. Genome Med 2: 41, 2010.
17. Liseth K, Ersvaer E, Hervig T and Bruserud O: Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience. J Biomed Biotechnol 2010: 692097, 2010.
18. Chaput N, De Botton S, Obeid M, et al: Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. J Mol Med 85: 1069-1076, 2007.
19. Ryningen A, Stapnes C, Lassalle P, Corbascio M, Gjertsen BT and Bruserud O: A subset of patients with high-risk acute myelogenous leukemia shows improved peripheral blood cell counts when treated with the combination of valproic acid, theophylline and all-trans retinoic acid. Leuk Res 33: 779-787, 2009.
20. Ryningen A, Stapnes C, Paulsen K, Lassalle P, Gjertsen BT and Bruserud O: In vivo biological effects of ATRA in the treatment of AML. Expert Opin Investig Drugs 17: 1623-1633, 2008.
21. Bruserud O, Gjertsen BT, Foss B and Huang TS: New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells-the present use in experimental studies and the possible importance for future therapeutic approaches. Stem Cells 19: 1-11, 2001.
22. Bruserud O: Effect of dipyridamole, theophyllamine and verapamil on spontaneous in vitro proliferation of myelogenous leukaemia cells. Acta Oncol 31: 53-58, 1992.
23. Bruserud O, Gjertsen BT and von Volkman HL: In vitro culture of human acute myelogenous leukemia (AML) cells in serum-free media: studies of native AML blasts and AML cell lines. J Hematother Stem Cell Res 9: 923-932, 2000.
24. Stapnes C, Ryningen A, Hatfield K, et al: Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors. Int J Oncol 31: 1529-1538, 2007.
25. Bruserud O, Hovland R, Wergeland L, Huang TS and Gjertsen BT: Flt3-mediated signaling in human acute myelogenous leukemia (AML) blasts: a functional characterization of Flt3-ligand effects in AML cell populations with and without genetic Flt3 abnormalities. Haematologica 88: 416-428, 2003.
26. Bruserud O, Huang TS, Glenjen N, Gjertsen BT and Foss B: Leptin in human acute myelogenous leukemia: studies of in vivo levels and in vitro effects on native functional leukemia blasts. Haematologica 87: 584-595, 2002.
27. Ryningen A, Ersvaer E, Oyan AM, et al: Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90. Leuk Res 30: 1531-1540, 2006.
28. Casares N, Pequignot MO, Tesniere A, et al: Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 202: 1691-1701, 2005.
29. Weiden PL, Flournoy N, Thomas ED, et al: Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300: 1068-1073, 1979.
30. Del Poeta G, Venditti A, Del Principe MI, et al: Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood 101: 2125-2131, 2003.
31. Reikvam H, Ersvaer E and Bruserud O: Heat shock protein 90-a potential target in the treatment of human acute myelogenous leukemia Curr Cancer Drug Targets 9: 761-776, 2009.
32. Bruserud O, Ryningen A, Wergeland L, Glenjen NI and Gjertsen BT: Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica 89: 391-402, 2004.
33. Stapnes C, Doskeland AP, Hatfield K, et al: The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells. Br J Haematol 136: 814-828, 2007.
34. Corver WE, Cornelisse CJ and Fleuren GJ: Simultaneous measurement of two cellular antigens and DNA using fluorescein-isothiocyanate, R-phycoerythrin, and propidium iodide on a standard FACScan. Cytometry 15: 117-128, 1994.
35. Mrozek K, Heerema NA and Bloomfield CD: Cytogenetics in acute leukemia. Blood Rev 18: 115-136, 2004.